Is it now time to prepare psychiatry for a psychedelic future?
The British Journal of Psychiatry May 20, 2024 David Nutt, Ilana Crome, Allan H Young 18 citations
Australia has reclassified psilocybin and MDMA from prohibited substances to prescription medicines for treatment-resistant depression and post-traumatic stress disorder, respectively. The feature examines the rationale behind these regulatory changes, the potential benefits and difficulties they present to psychiatric practice, and how mental health professionals and healthcare systems can adapt to integrate these treatments.